DTP vaccine

See also: DPT vaccine

DTP vaccine

Global vaccination coverage- diphtheria-tetanus-pertussis (DTP3) immunization
Combination of
Diphtheria	Vaccine
Tetanus	Vaccine
Pertussis	Vaccine
Clinical data
Trade names	REVAXIS
AHFS/Drugs.com	UK Drug Information
Routes of administration	Intramuscular injection
Identifiers
CAS Number	863488-19-1 Y
ChemSpider	none

DTP is a combination vaccine against three infectious diseases in humans: diphtheria, tetanus, and Pertussis. This is used in the United Kingdom, the Netherlands, and France.

Brand names include REVAXIS (Sanofi Pasteur).

By country

In the United Kingdom, DTP is called the "3-in-1 teenage booster" and protects against tetanus, diphtheria and polio. It is given by the NHS to all teenagers aged 14. (The hexavalent vaccine is given to infants and provides the first stage of protection against diphtheria, tetanus, and polio, as well as pertussis, Haemophilus influenzae type B and Hepatitis B). Subsequent boosters are recommended for foreign travellers where more than 10 years has passed since their last booster. This is provided on the NHS free of charge due to the significant risk that an imported case of polio could pose to public health in Britain.

In France, DTP is mandatory and given at 2 months (1st dose) and 4 months (2nd dose) with a booster at 11 months. Subsequent boosters are recommended at ages 6, 11-13, 25, 45, 65, then every ten years.

In the Netherlands, DTP is given as part of the National Immunisation Programme.